Immunotherapy for non-small cell lung cancer: from clinical trials to real-world practice.
作者信息
Rashdan Sawsan, Gerber David E
机构信息
Division of Hematology-Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.
出版信息
Transl Lung Cancer Res. 2019 Jun;8(3):202-207. doi: 10.21037/tlcr.2018.09.15.
Abstract
摘要
相似文献
1
Immunotherapy for non-small cell lung cancer: from clinical trials to real-world practice.非小细胞肺癌的免疫疗法：从临床试验到实际应用
Transl Lung Cancer Res. 2019 Jun;8(3):202-207. doi: 10.21037/tlcr.2018.09.15.
2
An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non-Small-Cell Lung Cancer.评估晚期非小细胞肺癌免疫治疗患者结局的真实世界终点的探索性分析
JCO Clin Cancer Inform. 2019 Jul;3:1-15. doi: 10.1200/CCI.18.00155.
3
Real-world outcomes of immunotherapy-based regimens in first-line advanced non-small cell lung cancer.免疫疗法为基础的一线治疗方案在晚期非小细胞肺癌中的真实世界结局。
Lung Cancer. 2021 Jun;156:41-49. doi: 10.1016/j.lungcan.2021.04.007. Epub 2021 Apr 14.
4
[A Single Center Analysis of Advanced Non-small Cell Lung Cancer Patients Treated with Immunotherapy in Real-world Practice].[真实世界中接受免疫治疗的晚期非小细胞肺癌患者的单中心分析]
Zhongguo Fei Ai Za Zhi. 2019 Nov 20;22(11):687-695. doi: 10.3779/j.issn.1009-3419.2019.11.02.
5
Real-World Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval.美国监管批准后一年接受程序性死亡蛋白 1 抑制剂治疗的转移性非小细胞肺癌患者的真实世界结局。
Oncologist. 2019 May;24(5):648-656. doi: 10.1634/theoncologist.2018-0307. Epub 2018 Dec 27.
6
Real-world progression-free survival in first-line advanced non-small cell lung cancer treated with immunotherapy-based regimens using a US dataset.使用美国数据集的基于免疫疗法方案治疗的一线晚期非小细胞肺癌的真实世界无进展生存期
Data Brief. 2021 Jun 6;37:107195. doi: 10.1016/j.dib.2021.107195. eCollection 2021 Aug.
7
Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands.荷兰 IV 期非小细胞肺癌（NSCLC）免疫治疗的真实世界结局与临床试验结果对比。
Sci Rep. 2021 Mar 18;11(1):6306. doi: 10.1038/s41598-021-85696-3.
8
Keeping it real: implications of real-world treatment outcomes for first-line immunotherapy in metastatic non-small-cell lung cancer.保持真实：真实世界治疗结果对转移性非小细胞肺癌一线免疫治疗的影响。
Immunotherapy. 2021 Dec;13(18):1453-1456. doi: 10.2217/imt-2021-0237. Epub 2021 Oct 13.
9
Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative.葡萄牙免疫治疗时代前晚期非小细胞肺癌的真实世界治疗模式和生存结局：来自 I-O Optimise 计划的回顾性分析。
BMC Pulm Med. 2020 Sep 10;20(1):240. doi: 10.1186/s12890-020-01270-z.
10
Immunotherapy as second-line treatment and beyond for non-small cell lung cancer in a single center of China: Outcomes, toxicities, and clinical predictive factors from a real-world retrospective analysis.免疫疗法作为二线治疗及以上方案用于中国单中心的非小细胞肺癌：一项真实世界回顾性分析的结局、毒性和临床预测因素。
Thorac Cancer. 2020 Jul;11(7):1955-1962. doi: 10.1111/1759-7714.13488. Epub 2020 May 29.
引用本文的文献
1
Durvalumab after sequential chemoradiotherapy in unresectable stage III non-small-cell lung cancer-final analysis from the phase II PACIFIC-6 trial.不可切除的 III 期非小细胞肺癌序贯放化疗后使用度伐鲁单抗——II 期 PACIFIC-6 试验的最终分析
ESMO Open. 2025 Jun;10(6):105071. doi: 10.1016/j.esmoop.2025.105071. Epub 2025 May 27.
2
Cost-effectiveness of atezolizumab versus chemotherapy in patients with non-small-cell lung cancer ineligible for platinum-based doublet chemotherapy.阿特珠单抗与化疗用于不适合铂类双药化疗的非小细胞肺癌患者的成本效益
Front Public Health. 2025 May 2;13:1349645. doi: 10.3389/fpubh.2025.1349645. eCollection 2025.
3
Association of systemic therapy with survival among adults with advanced non-small cell lung cancer.全身治疗与晚期非小细胞肺癌成年患者生存率的关联
Transl Lung Cancer Res. 2025 Jan 24;14(1):176-193. doi: 10.21037/tlcr-24-749. Epub 2025 Jan 22.
4
Exploring the value of routinely collected data on EQ-5D-5L and other electronic patient-reported outcome measures as prognostic factors in adults with advanced non-small cell lung cancer receiving immunotherapy.探索常规收集的EQ-5D-5L数据及其他电子患者报告结局指标作为接受免疫治疗的晚期非小细胞肺癌成年患者预后因素的价值。
BMJ Oncol. 2024 May 15;3(1):e000158. doi: 10.1136/bmjonc-2023-000158. eCollection 2024.
5
Real-world evidence for pembrolizumab in non-small cell lung cancer: a nationwide cohort study.帕博利珠单抗治疗非小细胞肺癌的真实世界证据：一项全国性队列研究。
Br J Cancer. 2025 Jan;132(1):93-102. doi: 10.1038/s41416-024-02895-1. Epub 2024 Nov 3.
6
Highly consistency of mutation spectrum between circulating tumor DNA and paired tissue in lung cancer patients.肺癌患者循环肿瘤DNA与配对组织之间的突变谱高度一致。
Heliyon. 2024 Jul 4;10(13):e34013. doi: 10.1016/j.heliyon.2024.e34013. eCollection 2024 Jul 15.
7
Patterns of immunotherapy utilization for non-small cell lung cancer in Texas pre- and post-regulatory approval.德克萨斯州免疫疗法在非小细胞肺癌中的应用模式：监管批准前后。
Clin Transl Oncol. 2024 Aug;26(8):1908-1920. doi: 10.1007/s12094-024-03412-9. Epub 2024 Mar 30.
8
Uptake of novel systemic therapy: Real world patterns among adults with advanced non-small cell lung cancer.新型全身治疗药物的应用：晚期非小细胞肺癌成人患者的真实世界模式。
Cancer Treat Res Commun. 2023;36:100730. doi: 10.1016/j.ctarc.2023.100730. Epub 2023 Jun 14.
9
Health outcomes and healthcare resource utilization among Veterans with stage IV non-small cell lung cancer treated with second-line chemotherapy versus immunotherapy.二线化疗与免疫治疗用于治疗 IV 期非小细胞肺癌的退伍军人的健康结果和医疗资源利用。
PLoS One. 2023 Feb 21;18(2):e0282020. doi: 10.1371/journal.pone.0282020. eCollection 2023.
10
Immunotherapeutics in lung cancers: from mechanistic insight to clinical implications and synergistic perspectives.肺癌免疫疗法：从机制洞察到临床意义及协同作用视角
Mol Biol Rep. 2023 Mar;50(3):2685-2700. doi: 10.1007/s11033-022-08180-9. Epub 2022 Dec 19.
本文引用的文献
1
Real world data of nivolumab for previously treated non-small cell lung cancer patients: a Galician lung cancer group clinical experience.纳武利尤单抗用于既往治疗的非小细胞肺癌患者的真实世界数据：加利西亚肺癌组的临床经验。
Transl Lung Cancer Res. 2018 Jun;7(3):404-415. doi: 10.21037/tlcr.2018.04.03.
2
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.阿替利珠单抗作为转移性非鳞状 NSCLC 一线治疗药物。
N Engl J Med. 2018 Jun 14;378(24):2288-2301. doi: 10.1056/NEJMoa1716948. Epub 2018 Jun 4.
3
Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials.程序性细胞死亡蛋白 1 免疫检查点抑制剂的采用速度及其与关键性临床试验中患者年龄的比较。
JAMA Oncol. 2018 Aug 1;4(8):e180798. doi: 10.1001/jamaoncol.2018.0798. Epub 2018 Aug 9.
4
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.帕博利珠单抗联合化疗治疗转移性非小细胞肺癌。
N Engl J Med. 2018 May 31;378(22):2078-2092. doi: 10.1056/NEJMoa1801005. Epub 2018 Apr 16.
5
Durvalumab in Stage III Non-Small-Cell Lung Cancer.度伐利尤单抗用于III期非小细胞肺癌
N Engl J Med. 2018 Mar 1;378(9):869-870. doi: 10.1056/NEJMc1716426.
6
Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153.纳武利尤单抗 30 分钟输注的安全性特征：CheckMate 153 数据分析。
Cancer Chemother Pharmacol. 2018 Apr;81(4):679-686. doi: 10.1007/s00280-018-3527-6. Epub 2018 Feb 13.
7
Concomitant use of corticosteroids and immune checkpoint inhibitors in patients with hematologic or solid neoplasms: A systematic review.伴用皮质类固醇和免疫检查点抑制剂治疗血液系统或实体瘤患者：系统评价。
Crit Rev Oncol Hematol. 2017 Dec;120:86-92. doi: 10.1016/j.critrevonc.2017.10.009. Epub 2017 Oct 27.
8
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).阿特珠单抗作为程序性死亡配体1筛选的晚期非小细胞肺癌患者一线或后续治疗的II期试验（BIRCH）
J Clin Oncol. 2017 Aug 20;35(24):2781-2789. doi: 10.1200/JCO.2016.71.9476. Epub 2017 Jun 13.
9
Components in aqueous flower extract inhibit melanoma cell growth.水性花提取物中的成分可抑制黑色素瘤细胞的生长。
J Tradit Complement Med. 2016 Feb 23;7(1):45-49. doi: 10.1016/j.jtcme.2016.01.005. eCollection 2017 Jan.
10
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.阿特珠单抗对比多西他赛用于既往治疗过的非小细胞肺癌患者（OAK）：一项3期、开放标签、多中心随机对照试验
Lancet. 2017 Jan 21;389(10066):255-265. doi: 10.1016/S0140-6736(16)32517-X. Epub 2016 Dec 13.
Zotero 插件